Skip to main content
. 2022 Oct 3;9:994160. doi: 10.3389/fmed.2022.994160

FIGURE 2.

FIGURE 2

Neutralizing antibody responses to pseudoviral SARS-CoV-2-S after COVID-19 vaccination: (A) The 50% neutralization titers (NT50) induced by primary COVID-19 vaccination with BNT162b2 (n = 22), mRNA-1273 (n = 24), ChAdOx1/mRNA (n = 20) or Ad26.COV2.S (n = 19) quantified by the pseudovirus neutralization assay. Data from convalescent comparators (n = 25) are also displayed, but are not included in the statistical analysis. (B) NT50 values merged for all vaccine types. (C) The frequency of quantifiable (> 25) and non-quantifiable (≤ 25) NT50 values merged for all vaccine types. From left to right: SARS-CoV-2-S wt (Wuhan-Hu-1 including D614G) and the following SARS-CoV-2-S VOCs: B.1.1.7 (Alpha), B.1.617.2 (Delta), B.1.351 (Beta) and B.1.1.529; BA.1 (Omicron) (B.1.1.529; BA.1, n = 32: eight individuals per vaccine group). All boxplots present the lower quartile, median and upper quartile, and the error bars indicate 95% CI. P-values were indicated as follows: *p ≤ 0.05, **p < 0.01, and ****p < 0.0001.